BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15068001)

  • 1. Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
    Ala A; Dieterich DT
    AIDS Read; 2004 Mar; 14(3):134-5. PubMed ID: 15068001
    [No Abstract]   [Full Text] [Related]  

  • 2. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Reijnders JG; Janssen HL
    J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
    Avihingsanon A; Lewin SR; Kerr S; Chang JJ; Piyawat K; Napissanant N; Matthews GV; Dore GJ; Bowden S; Lange J; Ruxrungtham K
    Antivir Ther; 2010; 15(6):917-22. PubMed ID: 20834105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou Y; Tubiana R; Thibault V
    N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment: a tale of two viruses.
    Dieterich DT
    AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV and hepatitis B virus: options for managing coinfection.
    Dieterich DT
    Top HIV Med; 2003; 11(1):16-9. PubMed ID: 12717046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of chronic hepatitis B in the HIV-infected patient.
    Thio CL
    AIDS Read; 2004 Mar; 14(3):122-9, 133, 136-7. PubMed ID: 15068000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
    Soriano V; Puoti M; Bonacini M; Brook G; Cargnel A; Rockstroh J; Thio C; Benhamou Y
    AIDS; 2005 Feb; 19(3):221-40. PubMed ID: 15718833
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
    Schirmer P; Winters M; Holodniy M
    J Clin Virol; 2011 Nov; 52(3):261-4. PubMed ID: 21840252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
    AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatment of chronic hepatitis B.
    Lok AS
    Semin Liver Dis; 2004; 24 Suppl 1():77-82. PubMed ID: 15192805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 17. A controlled trial of initial antiviral regimens for HIV-1 infection.
    Parienti JJ
    N Engl J Med; 2010 Mar; 362(9):854; author reply 855. PubMed ID: 20200393
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
    AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approaches in the treatment of hepatitis B].
    Sagir A; Avci A; Erhardt A; Lörke J; Heintges T; Häussinger D
    Dtsch Med Wochenschr; 2004 May; 129(21):1203-8. PubMed ID: 15160325
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.